Tofacitinib (CP-690,550), an oral JAK inhibitor, in c

【作者】（必须） [13]    Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M.
    【文章标题】（必须）Tofacitinib (CP-690,550), an oral JAK inhibitor, in combination with traditional DMARDS: phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDS.
    【期刊名，年份，卷（期），起止页*****】（期刊名必须，其他为快速获得应助请尽量填写） Annals of the Rheumatic Diseases 2011;70(Supple3):170
    【全文链接】 （为快速获得应助请尽量填写）